Oncolytics Biotech Inc. (ONCY) Bundle
A Brief History of Oncolytics Biotech Inc. (ONCY)
Foundation and Early Years
Oncolytics Biotech Inc. was founded in 1998, focusing on developing oncolytic virus therapies for cancer treatment. The company's lead product candidate is REOLYSIN, a formulation based on the reovirus, which selectively infects and kills cancer cells while sparing normal cells.
Initial Public Offerings and Funding
Oncolytics went public in 2000, trading on the Toronto Stock Exchange under the ticker symbol ONC. In 2004, the company raised $9 million in an equity financing round. By 2008, Oncolytics had secured approximately $30 million from multiple financing activities.
Clinical Trials and Development Progress
The initial clinical trials for REOLYSIN began in 2004. By 2010, the company reported promising results in Phase 1/2 clinical trials for various cancers, including head and neck cancers. In 2017, results from a Phase 2 trial indicated an improved overall survival rate for patients treated with REOLYSIN combined with chemotherapy.
| Year | Trial Phase | Cancer Type | Results |
|---|---|---|---|
| 2004 | Phase 1 | Various | Initial safety assessment |
| 2010 | Phase 1/2 | Head and Neck | Promising response rates |
| 2017 | Phase 2 | Multiple Myeloma | Improved overall survival |
Financial Performance and Market Presence
Throughout the years, Oncolytics has reported fluctuating revenues. For the fiscal year ending December 31, 2022, the company reported revenues of approximately $1.5 million, primarily derived from collaboration agreements and licensing. As of September 30, 2023, Oncolytics reported cash and cash equivalents totaling $25 million.
Strategic Partnerships and Collaborations
Oncolytics has engaged in several collaborations to enhance its research and development. In 2021, the company partnered with Roche to evaluate the combination of REOLYSIN with targeted therapies. Additionally, strategic alliances with various academic institutions have supported its clinical programs.
Recent Developments and Future Directions
As of 2023, Oncolytics is actively working on several clinical trials, focusing on the efficacy of REOLYSIN in treating solid tumors in combination with immuno-oncology agents. The company aims to pave its way toward regulatory submissions in various jurisdictions.
| Year | Event | Impact |
|---|---|---|
| 2021 | Partnership with Roche | Enhanced clinical trial capabilities |
| 2022 | Phase 2 Clinical Trials | Progress in multiple indications |
| 2023 | Positive interim data | Increased investor interest |
Conclusion of Current Position
As of 2023, Oncolytics continues to advance its pipeline and explore new avenues for its lead product candidate, with an eye toward expanding its market presence and enhancing treatment options for cancer patients globally.
A Who Owns Oncolytics Biotech Inc. (ONCY)
Ownership Structure
Ownership Structure
Oncolytics Biotech Inc. (ticker symbol: ONCY) has an ownership structure that consists of institutional investors, retail investors, and company insiders. The following table presents the latest ownership data for Oncolytics Biotech Inc.
| Shareholder Type | Ownership Percentage | Number of Shares |
|---|---|---|
| Institutional Investors | 33.4% | 8,520,872 |
| Insiders | 6.1% | 1,538,000 |
| Retail Investors | 60.5% | 15,488,210 |
Major Institutional Shareholders
The following institutions hold significant stakes in Oncolytics Biotech Inc.:
| Institution | Shares Owned | Ownership Percentage |
|---|---|---|
| The Vanguard Group, Inc. | 1,900,000 | 7.6% |
| BlackRock, Inc. | 1,750,000 | 6.9% |
| State Street Corporation | 1,200,000 | 4.8% |
Insider Ownership
Company insiders play a vital role in the equity structure of Oncolytics Biotech Inc. The key figures include:
| Name | Position | Shares Owned |
|---|---|---|
| Dr. Brad Thompson | President & CEO | 600,000 |
| Dr. Keith A. Brinton | Chief Medical Officer | 400,000 |
| Ms. Lisa M. Pruitt | Director | 538,000 |
Stock Performance
The financial performance of Oncolytics Biotech Inc. can be evaluated through its recent stock performance statistics:
| Metric | Value |
|---|---|
| Current Stock Price (as of October 2023) | $2.13 |
| Market Capitalization | $53.25 million |
| 52-Week High | $5.15 |
| 52-Week Low | $1.81 |
Recent Funding and Investments
Oncolytics Biotech Inc. has secured various funding rounds contributing to its operational capabilities:
| Funding Round | Amount Raised | Date |
|---|---|---|
| Public Offering | $12 million | March 2023 |
| Private Placement | $15 million | August 2023 |
| Government Grant | $3 million | June 2023 |
Summary of Key Data
To synthesize the data presented, here is an overview of critical statistics relevant to Oncolytics Biotech Inc.:
| Statistic | Value |
|---|---|
| Total Shares Outstanding | 25,547,082 |
| Current Cash Reserves | $20 million |
| Annual Revenue (2022) | $1.2 million |
| Loss Per Share (2022) | ($0.45) |
Oncolytics Biotech Inc. (ONCY) Mission Statement
Company Overview
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing oncolytic virus therapies for cancer treatment. The company's lead product, Pelareorep, is an intravenous formulation of the reovirus with a mission to provide innovative therapies that target cancer effectively.
Mission Statement
The mission of Oncolytics Biotech Inc. is to innovate and develop oncolytic virus therapies that can turn cancer into a manageable chronic illness, significantly improving patient outcomes and quality of life.
Strategic Objectives
- Advancing clinical development of Pelareorep in various cancer indications.
- Establishing collaborations with key opinion leaders and research institutions.
- Engaging in partnerships that enhance the potential of oncolytic virus therapies.
- Increasing awareness and understanding of oncolytic virotherapy in the medical community.
Current Developments
Oncolytics Biotech Inc. continues to focus on clinical trials involving Pelareorep, with a special emphasis on its efficacy in combination with immunotherapies. As of Q3 2023, the company reported:
| Event | Date | Details |
|---|---|---|
| Phase 2 Clinical Trial | July 2023 | Started a trial evaluating Pelareorep in combination with pembrolizumab for metastatic breast cancer. |
| Financial Results | August 2023 | Reported a cash position of $30 million, sufficient to fund operations into 2025. |
| Collaboration Agreement | September 2023 | Entered a partnership with a leading immunotherapy company to explore combination therapies. |
Financial Overview
As of Q3 2023, the financial performance indicators of Oncolytics Biotech Inc. are as follows:
| Financial Metric | Q2 2023 | Q3 2023 |
|---|---|---|
| Revenue | $500,000 | $600,000 |
| Net Loss | $(5.2 million) | $(4.9 million) |
| R&D Expenses | $3.1 million | $2.9 million |
| Cash and Cash Equivalents | $25 million | $30 million |
Target Market
The target market for Oncolytics Biotech Inc. includes patients with:
- Metastatic breast cancer
- Non-small cell lung cancer (NSCLC)
- Head and neck cancers
- Pancreatic cancer
Vision for the Future
Oncolytics Biotech anticipates expanding its pipeline and aims to:
- Initiate additional clinical trials in 2024.
- Enhance the understanding of the mechanisms of oncolytic viruses.
- Focus on patient-centric approaches to enhance treatment outcomes.
Conclusion and Commitment
Oncolytics Biotech Inc. is dedicated to its mission of transforming cancer treatment through innovative therapies aimed at improving patient lives. With a demonstrated commitment to research and collaboration, Oncolytics Biotech is poised for growth in the evolving field of oncology.
How Oncolytics Biotech Inc. (ONCY) Works
Company Overview
Oncolytics Biotech Inc. (ONCY) is a biotechnology company focused on the development of oncolytic virus therapies for cancer treatment. The company is headquartered in Calgary, Alberta, Canada, and integrates advanced viral therapies into oncology.
Technology Platform
The primary technology utilized by Oncolytics is Reolysin, an oncolytic virus derived from the reovirus. This virus selectively infects and destroys cancer cells while sparing normal cells. Reolysin harnesses the body's immune response to enhance its therapeutic effects.
Pipeline and Clinical Trials
As of October 2023, Oncolytics has several clinical trials underway, particularly focusing on:
- Combining Reolysin with pembrolizumab in treating adult patients with advanced solid tumors.
- Investigating its effects in combination with chemotherapy in metastatic breast cancer.
- Conducting trials for various cancers including pancreatic, ovarian, and melanoma.
| Clinical Trial Phase | Indication | Status | Estimated Enrollment |
|---|---|---|---|
| Phase 1/2 | Metastatic Breast Cancer | Active | 60 |
| Phase 2 | Head and Neck Cancer | Active | 100 |
| Phase 2 | Pancreatic Cancer | Recruiting | 100 |
Financial Overview
As of the latest reported quarter in Q2 2023, Oncolytics Biotech had a total revenue of $1.2 million. The net loss for the same quarter was reported at $5.4 million. The company's cash and cash equivalents were approximately $25 million, providing a runway for ongoing clinical trials.
| Financial Metric | Q2 2023 Amount | Q1 2023 Amount |
|---|---|---|
| Total Revenue | $1.2 million | $1.0 million |
| Net Loss | $5.4 million | $6.2 million |
| Cash and Cash Equivalents | $25 million | $30 million |
Market Potential
The demand for innovative cancer therapies remains high, with the global oncology drugs market expected to reach approximately $250 billion by 2025. Oncolytics aims to position itself in this expanding market by leveraging its proprietary technology.
Partnerships and Collaborations
Oncolytics collaborates with various institutions to enhance its research capabilities. Notable partnerships include:
- Collaboration with Pfizer for combination therapies.
- Research agreement with the University of Texas MD Anderson Cancer Center.
Stock Performance
As of October 2023, Oncolytics Biotech’s stock price is approximately $1.50 per share. The market capitalization stands at around $85 million.
| Date | Stock Price | Market Capitalization | 52-Week Range |
|---|---|---|---|
| October 2023 | $1.50 | $85 million | $1.00 - $2.50 |
Conclusion on Future Prospects
Oncolytics Biotech Inc. continues to advance its innovative approach to cancer therapy, supported by clinical trials and strategic partnerships, aiming to make significant contributions to oncology.
How Oncolytics Biotech Inc. (ONCY) Makes Money
Revenue Generation from Product Development
Oncolytics Biotech Inc. focuses on the development and commercialization of immuno-oncology therapies. Their lead product, Reolysin, is a proprietary formulation of the reovirus that has shown promise in treating various types of cancer. The company's revenue largely hinges on successful trials and eventual product sales or licensing agreements.
Partnerships and Collaborations
Oncolytics has established various partnerships and collaborations to enhance its financial position. For instance, they entered into a partnership with Merck for clinical trials involving the combination of Reolysin and Merck's Keytruda. Such collaborations can result in funding and shared resources, benefitting both parties financially.
| Partnership | Partner Company | Focus Area | Financial Terms |
|---|---|---|---|
| Collaboration Agreement | Merck | Combination Therapy | Undisclosed upfront payment; shared milestone payments |
| Clinical Trial Cooperation | University of Alberta | Breast Cancer | Funding for trial costs |
Funding from Grants and Investments
Oncolytics typically secures grants and additional funding through various government programs and private investments. For example, in 2022, the company secured a total of $12 million in funding through government grants aimed at advancing their cancer therapies.
Public Offerings
To support its research and development, Oncolytics may issue public offerings. In 2021, they raised approximately $20 million in a public offering of common shares, which bolstered their operational funds.
Market Capitalization and Stock Performance
As of October 2023, Oncolytics Biotech has a market capitalization of approximately $200 million. The company’s stock performance is influenced by the progress of their clinical trials and news related to regulatory approvals.
| Date | Stock Price ($) | Market Cap ($ million) | Key Event |
|---|---|---|---|
| October 2023 | 3.50 | 200 | Phase 2 Trial Results |
| April 2023 | 2.80 | 150 | Collaboration with Merck Announced |
Licensing Agreements
Oncolytics also engages in licensing agreements to capitalize on their proprietary technology. In 2020, they signed a licensing agreement with Novartis, providing Novartis the rights to develop and commercialize products based on Oncolytics’ technology. The agreement included an upfront payment of $5 million and potential royalties.
Clinical Trial and Data Monetization
The company actively seeks to monetize its clinical trial data. The results from trials can be leveraged in negotiations with pharmaceutical companies for future development partnerships, which could yield significant financial returns.
Revenue from Patent Licensing
As part of their intellectual property strategy, Oncolytics holds several patents related to their therapies. Licensing these patents can provide a stream of revenue. As of 2023, the company has generated approximately $2 million through patent licensing agreements.
Investment in R&D to Drive Future Revenue
Oncolytics maintains a significant focus on research and development, with R&D expenses totaling around $15 million in 2022. The aim is to advance their lead product into new indications and expand their portfolio, potentially leading to new revenue streams.
Financial Metrics Summary
| Financial Metric | 2022 Amount ($ million) | 2023 Estimated Amount ($ million) |
|---|---|---|
| Revenue | 1.5 | 2.0 |
| R&D Expenses | 15 | 18 |
| Cash Reserves | 25 | 30 |
Oncolytics Biotech Inc. (ONCY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support